Alnylam Announces Positive Long-Term Data from ONPATTRO Trial
Alnylam Pharmaceuticals Inc. (ALNY) announced data from its Global Open Label Extension study of ONPATTRO for treating polyneuropathy of hereditary ATTR (hATTR) amyloidosis in adults. This interim 24 months data evaluated the drug candidate’s long-term efficacy and safety in eligible patients who completed the Phase 2 OLE (N=25) and APOLLO Phase 3 (N=186) studies.
The APOLLO Phase 3 trial was a randomized, double-blind, placebo-controlled, global study. The primary endpoint of the study was the change from baseline in modified Neuropathy Impairment Score +7 (mNIS+7) relative